Health ProductsDear Healthcare Professional Letter

Archived - Serious liver and skin toxicity in HIV uninfected individuals post-exposure prophylaxis

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

Notice about Health Canada advisories

[Text of letter begins]

Notice to Hospitals

Serious liver and skin toxicity in HIV uninfected individuals post-exposure prophylaxis

February 26, 2001

To: Hospital Chief of Medical Staff

Please distribute to prescribing and dispensing health professionals within your institution.

The Therapeutic Products Directorate (TPD) wishes to draw your attention to recent publicationsFootnote 1, Footnote 2, Footnote 3 identifying an association in HIV-uninfected individuals receiving multiple doses of VIRAMUNE in the setting of post-exposure prophylaxis (PEP) and serious liver and skin toxicity.

Revised safety information was added to the Canadian Product Monograph for VIRAMUNE (nevirapine), a non-nucleoside analog indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, December 29, 2000. Existing warnings in the Product Monograph for the risk of serious liver and skin toxicity with VIRAMUNE treatment were strengthened to include serious hepatotoxicity (including liver failure requiring transplantation in one instance) and serious skin rash (including Stevens-Johnson Syndrome) in HIV-uninfected individuals receiving multiple doses of VIRAMUNE in the setting of post-exposure prophylaxis, an unapproved use.

You are referred to the Product Monograph for recommendations regarding the use of VIRAMUNE in the setting of PEP.

Questions regarding this Notice should be directed to the Bureau of Pharmaceutical Assessment, Therapeutic Products Directorate at (613) 954-6015.

Any suspected adverse reactions can also be reported to:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or
Fax: (613) 957-0335
Toll free for consumers and health professionals: Tel: 866 234-2345,
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

References

Footnote 1

Dear Health Care Professional, Important Drug Warning, Boehringer Ingelheim, Columbus, Ohio, November 2000.

Return to footnote 1 referrer

Footnote 2

Dear Doctor or Pharmacist, Important Drug Warning Boehringer Ingelheim Canada Ltd, November 23, 2000.

Return to first footnote 2 referrer

Footnote 3

CDC MMWR Weekly. January 05, 2001 / 49(51); 1153-6, Serious Adverse Events Attributed to Nevirapine Regimens for Postexposure Prophylaxis After HIV Exposures-Worldwide, 1997-2000.

Return to footnote 3 referrer

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime